Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Abraxane + pegylated liposomal doxorubicin in relapsed/refractory DLBCL (≥2 prior lines)
ChiCTR-OIC-16008700Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, nab-paclitaxel and doxorubicin in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: complete response rate. Planned start Jul 2016; status: not yet recruiting.
02
Drugs
rituximabnab-paclitaxeldoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR-OIC-16008700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008700.